Twist Bioscience Corporation's stock surged 9.02% during pre-market trading following the release of its fiscal first quarter 2026 financial results, which featured revenue beats and raised full-year guidance.

The company reported Q1 revenue of $103.7 million, representing a 17% year-over-year increase and exceeding analyst estimates. Furthermore, Twist Bioscience provided optimistic forward-looking statements, forecasting Q2 revenue in the range of $107 million to $108 million, which also surpasses market expectations. The company raised its full-year revenue guidance to $435 million-$440 million, indicating confidence in its growth trajectory.

Additional positive metrics from the report include an improved gross margin of 52.0% and the company's reiterated expectation to achieve adjusted EBITDA breakeven in the fourth quarter of fiscal 2026. These combined factors of strong current performance, robust guidance, and a clear path toward profitability are driving investor optimism in the pre-market session.